Blueprint Medicines Corp · Q3 2022 earnings

Briefing

Blueprint Medicines announced its 2027 Blueprint to achieve precision medicine at scale and reported third quarter 2022 financial results.

Blueprint Medicines reported their Q3 2022 financial results and provided a business update, reaffirming their total revenue guidance for full-year 2022, while lowering product revenue guidance based on Q3 performance and near-term growth expectations. The company is on track to submit a supplemental new drug application for AYVAKIT in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023.

• On track to submit supplemental new drug application for AYVAKIT® (avapritinib) in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023.
• Reported updated data from the SYMPHONY trial of BLU-945 demonstrating clinical activity and a differentiated safety profile, supporting combination development in first-line EGFR-mutant non-small cell lung cancer.
• Expects to achieve the high-end of total revenue guidance of $180 million to $200 million for full-year 2022.
• Blueprint Medicines plans to highlight its 2027 Blueprint strategy to double its impact in five years across multiple metrics of portfolio strength at its Investor Day event.

Headline financials

Revenue & EPS history

Blueprint Medicines anticipates it will achieve the high end of previously provided revenue guidance for full-year 2022 of approximately $180 million to $200 million, including approximately $108 million to $111 million in AYVAKIT net product revenues. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.